2013
DOI: 10.1159/000346846
|View full text |Cite
|
Sign up to set email alerts
|

Vitamin D Treatment and Mortality in Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Abstract: Background/Aims: Hypovitaminosis D has been associated with an increased cardiovascular mortality in the general population and in patients with chronic kidney disease (CKD). Still, whether prescribing vitamin D reduces the risk of mortality in renal patients remains controversial. Methods: We searched PubMed, ClinicalTrials.gov and the Cochrane Library for long-term longitudinal studies comparing vitamin D compounds (25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and synthetic derivatives) to placebo or no trea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
80
0
1

Year Published

2013
2013
2022
2022

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 111 publications
(83 citation statements)
references
References 90 publications
2
80
0
1
Order By: Relevance
“…Vitamin D insufficiency is a well established occurrence in the progression of CKD, and has been linked to hyperparathyroidism and adynamic bone disease in these patients (Helvig et al, 2010;Holden et al, 2010). Furthermore, clinical studies have found that treatments with vitamin D receptor activators, such as calcitriol, reduce the risk of mortality in earlystage CKD patients and end-stage renal disease patients on dialysis treatments (Duranton et al, 2013). However, more recent evidence from the National Health and Nutrition Examination Survey and confirmed by Mursu et al (2015) indicates that the association between serum 25(OH)D and mortality is modified by magnesium intake (Deng et al, 2013;Mursu et al, 2015).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Vitamin D insufficiency is a well established occurrence in the progression of CKD, and has been linked to hyperparathyroidism and adynamic bone disease in these patients (Helvig et al, 2010;Holden et al, 2010). Furthermore, clinical studies have found that treatments with vitamin D receptor activators, such as calcitriol, reduce the risk of mortality in earlystage CKD patients and end-stage renal disease patients on dialysis treatments (Duranton et al, 2013). However, more recent evidence from the National Health and Nutrition Examination Survey and confirmed by Mursu et al (2015) indicates that the association between serum 25(OH)D and mortality is modified by magnesium intake (Deng et al, 2013;Mursu et al, 2015).…”
Section: Introductionmentioning
confidence: 99%
“…This calcitriol paradox likely relates to the dose, as amounts below 30 ng/kg have been shown to reduce VC (Mathew et al, 2008;Lau et al, 2012), whereas higher doses induce VC (Cardus et al, 2007;Koleganova et al, 2009;Duranton et al, 2013). These data suggest that calcitriol has a very narrow therapeutic window, thereby limiting its utility and benefit in therapy.…”
Section: Introductionmentioning
confidence: 99%
“…Observational studies have found that a poor vitamin D status is associated with an increased CVD incidence [25,26], and several studies have shown that administering VDRA to CKD patients improved survival prognosis and reduces the CVD incidence [15,16,17,18,19,20,21]. Meta-analyses have also confirmed the efficacy of VDRA [27,28]. However, earlier studies were limited in the predialysis or dialysis stage.…”
Section: Discussionmentioning
confidence: 99%
“…These data suggested that the protective effect of low dose vitamin D on vascular calcification may be related to the restoration of klotho expression. The impact of active vitamin D on survival were described in observational and retrospective studies mostly in hemodialysis patients [39][40][41][42] . Survival benefit was more pronounced in the groups of patients that received lower doses and was observed at all PTH levels.…”
Section: Active Vitamin Dmentioning
confidence: 99%